Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism.

Literature DB >> 3742146

Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism.

Abstract

MDL 72222, the selective 5-hydroxytryptamine (5-HT) M-receptor antagonist, prevented or reduced cisplatin-induced emesis in ferrets. It is suggested that cisplatin-induced, and possibly other cytotoxic drug-induced vomiting may involve a 5-HT M-receptor mechanism.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1986 PMID： 3742146 PMCID： PMC1916988 DOI： 10.1111/j.1476-5381.1986.tb10228.x

Source DB: PubMed Journal: Br J Pharmacol ISSN： 0007-1188 Impact factor: 8.739

10 in total

1. Cytotoxic-therapy-induced vomiting is mediated via enkephalin pathways.

Authors: A L Harris
Journal: Lancet Date: 1982-03-27 Impact factor: 79.321

Review 2. Neuronal connections of the area postrema.

Authors: R A Leslie; D G Gwyn
Journal: Fed Proc Date: 1984-12

3. A pilot study of high-dose domperidone as an antiemetic in patients treated with cisplatin.

Authors: M Tonato; F Roila; A del Favero; G Tognoni; M G Franzosi; S Pampallona
Journal: Eur J Cancer Clin Oncol Date: 1985-07

4. Cisplatin-induced emesis in the Ferret: a new animal model.

Authors: A P Florczyk; J E Schurig; W T Bradner
Journal: Cancer Treat Rep Date: 1982-01

5. Cisplatin-induced vomiting eliminated by ablation of the area postrema in cats.

Authors: L E McCarthy; H L Borison
Journal: Cancer Treat Rep Date: 1984-02

6. Neuronal 5-HT receptors in the periphery.

Authors: J R Fozard
Journal: Neuropharmacology Date: 1984-12 Impact factor: 5.250

Review 7. Metoclopramide. An updated review of its pharmacological properties and clinical use.

Authors: R A Harrington; C W Hamilton; R N Brogden; J A Linkewich; J A Romankiewicz; R C Heel
Journal: Drugs Date: 1983-05 Impact factor: 9.546

8. MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors.

Authors: J R Fozard
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1984-05 Impact factor: 3.000

9. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.

Authors: R J Gralla; L M Itri; S E Pisko; A E Squillante; D P Kelsen; D W Braun; L A Bordin; T J Braun; C W Young
Journal: N Engl J Med Date: 1981-10-15 Impact factor: 91.245

10. Ultrastructural localization of monoamines and peptides in rat area postrema.

Authors: V M Pickel; D M Armstrong
Journal: Fed Proc Date: 1984-12

10 in total

75 in total

1. Characterization of the 5-hydroxytryptamine receptors mediating contraction in the intestine of Suncus murinus.

Authors: F A Javid; R J Naylor
Journal: Br J Pharmacol Date: 1999-08 Impact factor: 8.739

Review 2. Neuropharmacology of emesis in relation to clinical response.

Authors: B Costall; R J Naylor
Journal: Br J Cancer Suppl Date: 1992-12

3. GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting.

Authors: M Marty; J P Droz; P Pouillart; B Paule; N Brion; J Bons
Journal: Cancer Chemother Pharmacol Date: 1989 Impact factor: 3.333

4. Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors.

Authors: A Hamik; S J Peroutka
Journal: Cancer Chemother Pharmacol Date: 1989 Impact factor: 3.333

5. A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy.

Authors: D B Smith; E S Newlands; G J Rustin; R H Begent; S M Crawford; K D Bagshawe; L Carruthers
Journal: Cancer Chemother Pharmacol Date: 1990 Impact factor: 3.333

6. Effects of granisetron and lorazepam, alone and in combination, on psychometric performance.

Authors: T J Leigh; C G Link; G L Fell
Journal: Br J Clin Pharmacol Date: 1991-03 Impact factor: 4.335

7. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group.

Authors: M Soukop
Journal: Support Care Cancer Date: 1994-05 Impact factor: 3.603